FRANKLIN LAKES, N.J. - BD (NYSE:BDX) announced today that its CentroVena One Insertion System received an Innovative Technology contract from Vizient, a healthcare performance improvement company. The $38.8 billion medical technology firm is a prominent player in the Healthcare Equipment & Supplies industry, according to InvestingPro data.
The contract was awarded after a review by hospital experts on Vizient’s client-led councils. The system is designed as an all-in-one central venous catheter insertion device that integrates the guidewire, needle, syringe and catheter into a single unit.
According to a head-to-head simulation study published in The Journal of Emergency Medicine in December 2025, the system showed 30% fewer steps and a 50% reduction in maximum procedure time compared to standard techniques. The study involved 49 participants.The innovation comes as BD maintains a "GOOD" financial health score and trades at what InvestingPro analysis suggests is an undervalued level relative to its Fair Value. The company has raised its dividend for 55 consecutive years, currently yielding 2.98%. For deeper insights into BD’s valuation and growth prospects, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities.
"Receiving a Vizient Innovative Technology contract recognizes the innovation behind CentroVena One and its potential to redefine how central lines are placed," said Eric Borin, worldwide president of Medication Delivery Solutions at BD.
The system incorporates design elements intended to address risks including contamination, air and guidewire embolism, needlestick injury and clinician blood exposure.
"Through the Vizient client-led council evaluation process, CentroVena One Insertion System demonstrated the potential to offer meaningful differentiation in today’s competitive landscape," said Kelly Flaharty, associate vice president of contract operations for Vizient.
Vizient represents a client base that includes academic medical centers, pediatric facilities, community hospitals and integrated health delivery networks, with a portfolio representing more than $156 billion in annual purchasing volume.
The information is based on a press release statement from BD. The company stated that simulation study results may not reflect actual clinical performance.
In other recent news, Becton Dickinson (BD) reported its Q2 2026 earnings, exceeding analyst expectations with an adjusted earnings per share (EPS) of $2.90, surpassing the forecasted $2.78. The company’s revenue reached $4.7 billion, slightly above the anticipated $4.67 billion. In addition to their earnings report, BD launched the Elyra Thulium Fiber Laser System for urologic stone management and soft tissue procedures, featuring an air-cooled design and available in two configurations, Elyra and Elyra Plus.
Furthermore, Becton Dickinson Euro Finance, a subsidiary of BD, completed a public offering of €600 million in notes due 2033, carrying a 3.855% interest rate. These notes are fully guaranteed by Becton, Dickinson and Company. In leadership changes, BD announced the appointment of Peter Menziuso as executive vice president and president of BD Interventional, effective June 1. Menziuso previously held a senior position at Johnson & Johnson.
Additionally, BD was among over 50 foreign pharmaceutical firms that participated in a roundtable meeting organized by China’s commerce ministry, indicating ongoing international engagement. These developments highlight BD’s active role in expanding its product offerings and strengthening its financial position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates BDX every month against thousands of alternatives using 100+ financial metrics.It found Siemens Energy (+231.5%) and Sandisk (+189%) before the crowd did. Could BDX be next—or is there a better opportunity in the same space?Don't wait to find out.